C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/113 (2010.01) A61K 31/7088 (2006.01) A61P 3/04 (2006.01) C12N 15/11 (2006.01) C12N 9/10 (2006.01) C12N 15/54 (2006.01)
Patent
CA 2729897
The present invention relates to oligomer compounds (oligomers), which target mtGPAT1mRNA in a cell, leading to reduced expression of mtGPAT1. Reduction of mtGPAT1 expression is beneficial for the treatment of certain medical disorders, such as overweight, obesity, fatty liver, hepatosteatosis, non alcoholic fatty liver disease (NAFLD), non alcoholic steatohepatitis(NASH), insulin resistance, and non insulin dependent diabetes mellitus (NIDDM).
La présente invention porte sur des composés oligomères (oligomères), qui ciblent l'ARNm de mtGPAT1 dans une cellule, ce qui conduit à l'expression réduite de mtGPAT1. La réduction de l'expression de mtGPAT1 est bénéfique pour le traitement de certains troubles pathologiques, tels que le surpoids, l'obésité, une stéatopathie hépatique, la stéatose hépatique, une stéatopathie hépatique non alcoolique (NAFLD), une stéatose hépatique non alcoolique (NASH), la résistance à l'insuline et le diabète sucré non insulinodépendant (NIDDM).
Lindholm Marie
Straarup Ellen Marie
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Santaris Pharma A/s
LandOfFree
Rna antagonist compounds for the inhibition of expression of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Rna antagonist compounds for the inhibition of expression of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rna antagonist compounds for the inhibition of expression of... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1812598